Compare GENB & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GENB | HRMY |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | GENB | HRMY |
|---|---|---|
| Price | $12.38 | $34.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $23.20 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 829.3K | 709.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $16.58 | $12.88 |
| P/E Ratio | ★ N/A | $64.00 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $11.00 | $25.52 |
| 52 Week High | $16.75 | $40.87 |
| Indicator | GENB | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 62.32 |
| Support Level | $11.67 | $25.92 |
| Resistance Level | $13.76 | $34.99 |
| Average True Range (ATR) | 1.08 | 1.10 |
| MACD | -0.10 | 0.39 |
| Stochastic Oscillator | 12.78 | 75.30 |
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.